• ქართული
  • English
  • Bristol-Myers says Celgene deal is 'best path' as investor opposition mounts

    Bristol-Myers Squibb urged shareholders on Wednesday to support its planned $74 billion takeover of Celgene Corp, as it faces opposition from at least two investors to what could be the largest pharmaceutical deal ever.

    Market Quotes by TradingView